KRAS and non-small cell lung carcinoma: For example, despite recent advances in the treatment of NSCLC with immune checkpoint inhibitors of PD1 and PD-L1, they have not shown a more pronounced effect in KRAS-mutant NSCLC compared to other NSCLC.